Avalo Therapeutics Inc
$ 18.32
-2.03%
07 Aug - close price
- Market Cap 1,002,881,000 USD
- Current Price $ 18.32
- High / Low $ 19.05 / 17.90
- Stock P/E N/A
- Book Value 2.77
- EPS -5.52
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.42 %
- ROE -0.89 %
- 52 Week High 24.27
- 52 Week Low 8.29
About
Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved diseases, particularly those related to immunological regulation. With a robust pipeline of proprietary drug candidates, Avalo is dedicated to addressing critical unmet medical needs in areas where effective treatments remain scarce. Leveraging in-depth insights into disease mechanisms alongside a rigorous clinical trial methodology, the company is well-positioned to achieve significant advancements in patient care. Through its patient-centric approach, Avalo not only seeks to improve therapeutic outcomes but also aims to make a substantial impact on the lives of those it serves, establishing itself as a noteworthy player in the biopharmaceutical landscape.
Analyst Target Price
$44.69
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-13 | 2026-03-23 | 2025-11-06 | 2025-08-07 | 2025-04-04 | 2025-03-27 | 2024-11-07 | 2024-07-11 | 2024-05-13 | 2024-03-28 | 2023-11-09 |
| Reported EPS | -0.83 | -0.98 | -0.37 | -2.19 | -1.92 | -1.25 | -2.74 | 0.98 | 4.21 | -141 | -116.21 | -26.4 |
| Estimated EPS | -0.66 | -1.03 | -1.495 | -1.64 | -1.43 | -1.6 | 1.665 | -1.19 | -6.7 | -1.18 | -4.8 | -264 |
| Surprise | -0.17 | 0.05 | 1.125 | -0.55 | -0.49 | 0.35 | -4.405 | 2.17 | 10.91 | -139.82 | -111.41 | 237.6 |
| Surprise Percentage | -25.7576% | 4.8544% | 75.2508% | -33.5366% | -34.2657% | 21.875% | -264.5646% | 182.3529% | 162.8358% | -11849.1525% | -2321.0417% | 90% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AVTX
2026-08-07 19:39:01
Guggenheim maintained a Buy rating for Avalo Therapeutics (AVTX) but lowered its price target from $50.00 to $48.00, reflecting a cautious outlook due to clinical development challenges. The stock is considered significantly overvalued with a GF Valueâ„¢ of $0.03 against a current price of $18.00, and a low GF Scoreâ„¢ of 23/100, indicating weak fundamentals, profitability, and growth. Insider selling further suggests a lack of confidence from those close to the company.
2026-08-07 14:39:01
FMR LLC has filed an amended Schedule 13G/A, disclosing a beneficial ownership of 5,737,966 shares of Avalo Therapeutics, Inc. (AVTX), which represents 10.8% of the company's common stock. The filing indicates FMR LLC holds sole dispositive power over all these shares and sole voting power over 5,737,946 shares, while Abigail P. Johnson is also listed as a beneficial owner with sole dispositive power but no voting power over the same number of shares. This report highlights the significant institutional stake in Avalo Therapeutics by FMR LLC and associated parties.
2026-08-07 12:39:01
State Street Corporation has disclosed a 5.5% beneficial ownership stake in Avalo Therapeutics, Inc. (AVTX) through a Schedule 13G filing. The investment firm reported owning 2,889,287 shares, with shared voting power over 2,837,724 shares and shared dispositive power over all 2,889,287 shares. Subsidiaries involved include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company.
2026-08-07 11:39:01
Avalo Therapeutics reported narrower losses for Q2 2026, with a net loss of $36.4M and a loss of $0.83 per share, significantly improving from the prior year. The clinical-stage biotechnology company is developing IL-1ß-based treatments and maintains a positive outlook from Wall Street analysts. The company continues to invest heavily in R&D, typical for biotech firms.
2026-08-06 23:20:00
This article provides a price-driven analysis for Avalo Therapeutics Inc. (NASDAQ: AVTX), highlighting weak near-term sentiment but potential long-term strength. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, along with a multi-timeframe signal analysis. The analysis emphasizes an exceptional risk-reward setup targeting a 22.7% gain against 0.3% risk.
2026-08-06 12:11:08
Avalo Therapeutics (Nasdaq: AVTX) announced its second-quarter 2026 financial results, highlighting plans to initiate a registrational Phase 3 program for abdakibart in hidradenitis suppurativa (HS) in the first half of 2027 and expanding its pipeline with AVTX-010. The company reported cash, cash equivalents, and investments of $472.2 million as of June 30, 2026, which are expected to fund operations into 2029. Despite an increased net loss compared to the previous year, Avalo's CEO emphasized a focus on advancing abdakibart towards Phase 3 and building a broader IL-1β franchise.
